Clinical Research Progress of the Non-Peptide Oral Somatostatin Receptor Ligand Paltusotine / 罕见病研究
JOURNAL OF RARE DISEASES
; (4): 414-419, 2023.
Article
in En
| WPRIM
| ID: wpr-1004968
Responsible library:
WPRO
ABSTRACT
The research and development of somatostatin analogues is a hot area in endocrinology and metabolism. The first generation octreotide, lanreotide and the second generation pareotide have been approved to be effective for the treatment of neuroendocrine tumors such as acromegaly. However, paltusotine, a somatostatin receptor ligand, is a novel non-peptide small molecule drug which can be administered orally and inhibits excessive secretion of growth hormone and insulin-like growth factor 1. This review summarizes the research progress of the pharmacokinetics, pharmacodynamics, clinical efficacy, telerability, and safety of paltusotine.
Full text:
1
Index:
WPRIM
Language:
En
Journal:
JOURNAL OF RARE DISEASES
Year:
2023
Type:
Article